Founding Partner, YuanMing Capital
YuanMing Capital is a healthcare specialty cross-border fund that invests in therapeutics, medical devices and diagnostics, as well as healthcare service companies based in the US and China. Prior to founding YuanMing Capital, Lawrence Tian established China International Futures Corporation and served as Chairman of China Chengtong Group. Since 2010, Mr. Tian has been committed to promoting China’s capital investment into US life science innovative companies and has successfully invested in leading biopharma companies including BeiGene, Ascentage Pharma, Mevion Medical Systems, Pharmacodia and CF PharmTech.
Mr. Tian obtained his master’s degree and doctoral degree from Wuhan University and was awarded the highest prize for economics in China: The China Economics Theory Innovation Award.